Bariatric surgery for non-alcoholic steatohepatitis in obese patients - PubMed (original) (raw)

Review

Bariatric surgery for non-alcoholic steatohepatitis in obese patients

Norberto C Chavez-Tapia et al. Cochrane Database Syst Rev. 2010.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly recognised as a condition associated with overweight or obesity that may progress to end-stage liver disease. NAFLD histology resembles alcohol-induced liver injury, but occurs in patients with no history of alcohol abuse. NAFLD has a broad spectrum of clinical and histological manifestations, ranging from simple fatty liver to hepatic steatosis with inflammation, advanced fibrosis, and cirrhosis. The inflammatory stage is known as non-alcoholic steatohepatitis (NASH). Recent reports indicate that weight loss induced by bariatric procedures could be beneficial for NASH treatment.

Objectives: To assess the benefits and harms of bariatric surgery for NASH in obese patients.

Search strategy: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded to October 2009.

Selection criteria: All randomised clinical trials evaluating any bariatric procedure versus no intervention, placebo (sham procedure), or other interventions in patients with NASH regardless of publication status, number of patients randomised, language, or blinding. Quasi-randomised clinical studies were to be considered for the review if no randomised clinical trials were identified. If included, their bias towards positive findings was to be considered.

Data collection and analysis: We extracted data in duplicate, and we planned to analyse the data by intention-to-treat.

Main results: We could not find any randomised clinical trials or quasi-randomised clinical studies that fulfilled the inclusion criteria. Our search resulted in twenty-one prospective or retrospective cohort studies, in which improvement on steatosis or inflammation scores was reported. However, four studies also described some deterioration in the degree of fibrosis.

Authors' conclusions: The lack of randomised clinical trials and quasi-randomised clinical studies precludes us to assess the benefits and harms of bariatric surgery as a therapeutic approach for patients with NASH. Limitations of all other studies with inferior design did not allow us to draw any unbiased conclusion on bariatric surgery for treatment of NASH.

PubMed Disclaimer

Conflict of interest statement

None known.

Update of

• doi: 10.1002/14651858.CD007340

Similar articles

• Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.
  Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Lirussi F, et al. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD004996. doi: 10.1002/14651858.CD004996.pub3. Cochrane Database Syst Rev. 2007. PMID: 17253535 Free PMC article. Review.
• Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
  Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Eslami L, et al. Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Cochrane Database Syst Rev. 2013. PMID: 24374462 Review.
• Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
  Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Lombardi R, et al. Cochrane Database Syst Rev. 2017 Mar 30;3(3):CD011640. doi: 10.1002/14651858.CD011640.pub2. Cochrane Database Syst Rev. 2017. PMID: 28358980 Free PMC article. Review.
• Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
  Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
• Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.
  Lirussi F, Mastropasqua E, Orando S, Orlando R. Lirussi F, et al. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD005165. doi: 10.1002/14651858.CD005165.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253543 Free PMC article. Review.

Cited by

• Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
  Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, Baffy G, Di Ciaula A. Portincasa P, et al. Int J Mol Sci. 2024 May 22;25(11):5640. doi: 10.3390/ijms25115640. Int J Mol Sci. 2024. PMID: 38891828 Free PMC article. Review.
• Emerging therapies for MASLD and their impact on plasma lipids.
  Nguyen M, Asgharpour A, Dixon DL, Sanyal AJ, Mehta A. Nguyen M, et al. Am J Prev Cardiol. 2024 Feb 5;17:100638. doi: 10.1016/j.ajpc.2024.100638. eCollection 2024 Mar. Am J Prev Cardiol. 2024. PMID: 38375066 Free PMC article.
• Cross-sectional study on stigma and motivation to adhere to lifestyle modification among vulnerable populations with fatty liver disease.
  Medina SP, Kim RG, Magee C, Stapper N, Khalili M. Medina SP, et al. Obes Sci Pract. 2023 Jun 21;9(6):581-589. doi: 10.1002/osp4.688. eCollection 2023 Dec. Obes Sci Pract. 2023. PMID: 38090690 Free PMC article.
• The Effect of Non-Alcoholic Fatty Liver Disease on Weight Loss and Resolution of Obesity-Related Disorders After Bariatric Surgery.
  Abdalla TSA, Giannou AD, Abdalla ASA, Izbicki JR, Dupreé A, Mann O, Wolter S. Abdalla TSA, et al. World J Surg. 2023 Dec;47(12):3281-3288. doi: 10.1007/s00268-023-07153-8. Epub 2023 Sep 25. World J Surg. 2023. PMID: 37747548 Free PMC article.
• Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention.
  Shao Y, Chen S, Han L, Liu J. Shao Y, et al. Nutr Metab (Lond). 2023 Jul 6;20(1):30. doi: 10.1186/s12986-023-00748-x. Nutr Metab (Lond). 2023. PMID: 37415199 Free PMC article. Review.

References

References to studies included in this review

Barker 2006 {published data only}

1. 1. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non‐alcoholic steatohepatitis: effect of Roux‐en‐Y gastric bypass surgery. American Journal of Gastroenterology 2006;101(2):368‐73. - PubMed

Clark 2005 {published data only}

1. 1. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux‐en‐Y gastric bypass improves liver histology in patients with non‐alcoholic fatty liver disease. Obesity Research 2005;13(7):1180‐6. - PubMed

Csendes 2006 {published data only}

1. 1. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obesity Surgery 2006;16(5):607‐11. - PubMed

de Almeida 2006 {published data only}

1. 1. Almeida SR, Rocha PR, Sanches MD, Leite VH, Silva RA, Diniz MT, et al. Roux‐en‐Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obesity Surgery 2006;16(3):270‐8. - PubMed

Dixon 2004 {published data only}

1. 1. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39(6):1647‐54. - PubMed

Dixon 2006 {published data only}

1. 1. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non‐alcoholic fatty liver disease: falls in gamma‐glutamyl transferase concentrations are associated with histologic improvement. Obesity Surgery 2006;16(10):1278‐86. - PubMed

Furuya 2007 {published data only}

1. 1. Furuya CK Jr, Oliveira CP, Mello ES, Faintuch J, Raskovski A, Matsuda M, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. Journal of Gastroenterol Hepatology 2007;22(4):510‐4. - PubMed

Jaskiewicz 2006 {published data only}

1. 1. Jaskiewicz K, Raczynska S, Rzepko R, Sledziński Z. Nonalcoholic fatty liver disease treated by gastroplasty. Digestive Diseases and Sciences 2006;51(1):21‐6. - PubMed

Keshishian 2005 {published data only}

1. 1. Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obesity Surgery 2005;15(10):1418‐23. - PubMed

Klein 2006 {published data only}

1. 1. Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006;130(6):1564‐72. - PubMed

Kral 2004 {published data only}

1. 1. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135(1):48‐58. - PubMed

Liu 2007 {published data only}

1. 1. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obesity Surgery 2007;17(4):486‐92. - PubMed

Luyckx 1998 {published data only}

1. 1. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. International Journal of Obesity and Related Metabolic Disorders 1998;22(3):222‐6. - PubMed

Mathurin 2006 {published data only}

1. 1. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006;130(6):1617‐24. - PubMed

Mathurin 2009 {published data only}

1. 1. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long‐term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137:532‐40. - PubMed

Mattar 2005 {published data only}

1. 1. Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas‐Mitchell E, et al. Surgically‐induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Annals of Surgery 2005;242(4):610‐7. - PMC - PubMed

Meinhardt 2006 {published data only}

1. 1. Meinhardt NG, Souto KE, Ulbrich‐Kulczynski JM, Stein AT. Hepatic outcomes after jejunoileal bypass: is there a publication bias?. Obesity Surgery 2006;16(9):1171‐8. - PubMed

Mottin 2005 {published data only}

1. 1. Mottin CC, Moretto M, Padoin AV, Kupski C, Swarowsky AM, Glock L, et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obesity Surgery 2005;15:788‐93. - PubMed

Ranløv 1990 {published data only}

1. 1. Ranløv I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990;47(4):208‐14. - PubMed

Silverman 1995 {published data only}

1. 1. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. American Journal of Clinical Pathology 1995;104(1):23‐31. - PubMed

Stratopoulos 2005 {published data only}

1. 1. Stratopoulos C, Papakonstantinou A, Terzis I, Spiliadi C, Dimitriades G, Komesidou V, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obesity Surgery 2005;15:1154‐60. - PubMed

Additional references

Adams 2005

1. 1. Adams LA, Lymp JF, Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population‐based cohort study. Gastroenterology 2005;129(1):113‐21. - PubMed

Aithal 2008

1. 1. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo‐controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135(4):1176‐84. - PubMed

Angulo 2006

1. 1. Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver International 2006;26(10):1209‐16. - PubMed

Bedogni 2005

1. 1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42(1):44‐52. - PubMed

Belfort 2006

1. 1. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo‐controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England Journal of Medicine 2006;355(322):2297‐307. - PubMed

Bellentani 2008

1. 1. Bellentani S, Bedogni G, Tiribelli C. Liver and heart: a new link?. Journal of Hepatology 2008;49(2):300‐2. - PubMed

Berg 2005

1. 1. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 2005;96(9):939‐49. - PubMed

Brunt 1999

1. 1. Brunt EM, Janney CG, Bisceglie AM, Neuschwander‐Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American Journal of Gastroenterology 1999;94(9):2467‐74. - PubMed

Byron 1996

1. 1. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital‐based practice. Hepatology 1996;24(4):813‐5. - PubMed

Chavez‐Tapia 2006

1. 1. Chavez‐Tapia NC, Tellez‐Avila FI, Garcia‐Leiva J, Uribe‐Ramos MH, Sanchez‐Avila F, Uribe M. Therapeutic aspects in nonalcoholic steatohepatitis. Literature review. Revista de Gastroenterología de México 2006;71(4):487‐95. - PubMed

Chavez‐Tapia 2009

1. 1. Chavez‐Tapia N, Mendez‐Sanchez N, Uribe M. Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Annals of Hepatology 2009;8(1 Suppl):34‐9. - PubMed

Chavez‐Tapia 2009a

1. 1. Chávez‐Tapia NC, Uribe M, Ponciano‐Rodríguez G, Medina‐Santillán R, Méndez‐Sánchez N. New insights into the pathophysiology of nonalcoholic fatty liver disease. Annals of Hepatology 2009;8(1 Suppl):9‐17. - PubMed

Chavez‐Tapia 2009b

1. 1. Chavez‐Tapia NC, Tellez‐Avila FA, Valdes‐Escarcega M, Perez‐Bautista O, Lizardi‐Cervera J, Méndez‐Sanchez N, et al. Differential risk factor patterns for a positive treadmill test among subjects with and without ultrasound‐based fatty liver. Archives of Medical Science 2009;5(2):207‐14.

Colquitt 2009

1. 1. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD003641.pub3] - DOI - PubMed

Day 1998

1. 1. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party?. Hepatology 1998;27(6):1463‐6. - PubMed

DeMets 1987

1. 1. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. - PubMed

DerSimonian 1986

1. 1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed

Egger 1997

1. 1. Egger M, Davey SG, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. - PMC - PubMed

Falck‐Ytter 2001

1. 1. Falck‐Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Seminars in Liver Disease 2001;21(1):17‐26. - PubMed

Fassio 2004

1. 1. Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40(4):820‐6. - PubMed

Garcia‐Monzon 2001

1. 1. Garcia‐Monzon. Non‐alcoholic steatohepatitis. Gastroenterologia y Hepatologia 2001;24(8):395‐402. - PubMed

Gluud 2009

1. 1. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen B, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2009, Issue 4. Art. No.: LIVER.

Goldstein 2004

1. 1. Goldstein BJ, Scalia R. A novel adipokine linking adipocytes and vascular function. Journal of Clinical Endocrinology & Metabolism 2004;89(6):2563‐8. - PubMed

Guyatt 2008

1. 1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2008;336(7650):924‐6. - PMC - PubMed

Higgins 2002

1. 1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21:1539‐58. - PubMed

Higgins 2008

1. 1. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Intervention 5.0.0 [updated February 2008 ]. The Cochrane Collaboration 2008.

Hotamisligil 1995

1. 1. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor‐alpha in human obesity and insulin resistance. The Journal of Clinical Investigation 1995;95(5):2409‐15. - PMC - PubMed

ICH‐GCP 1996

1. 1. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Guideline for Good Clinical Practice. E6 (R1). ICH Harmonised Tripartite Guideline 1996.

Kjaergard 2001

1. 1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed

Lirussi 2007

1. 1. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non‐alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005165.pub2] - DOI - PMC - PubMed

Livingston 2006

1. 1. Livingston EH, Langert J. The impact of age and medicare status on bariatric surgical outcomes. Archives of Surgery 2006;141(11):1115‐20. - PubMed

Lizardi‐Cervera 2007

1. 1. Lizardi‐Cervera J, Chavez‐Tapia NC, Pérez‐Bautista O, Ramos MH, Uribe M. Association among C‐reactive protein, fatty liver disease, and cardiovascular risk. Digestive Diseases and Sciences 2007;52(9):2375‐9. - PubMed

Lizardi‐Cervera 2009

1. 1. Lizardi‐Cervera J, Aguilar‐Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Annals of Hepatology 2009;8(1 Suppl):40‐3. - PubMed

Matteoni 1999

1. 1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413‐9. - PubMed

Mendez‐Sanchez 2005

1. 1. Mendez‐Sanchez N, Villa AR, Chavez‐Tapia NC, Ponciano‐Rodriguez G, Almeda‐Valdes P, Gonzalez D, et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Annals of Hepatology 2005;4(1):52‐5. - PubMed

Moher 1998

1. 1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses. Lancet 1998;352(9128):609‐13. - PubMed

Montori 2004

1. 1. Montori VM, Saha S, Clarke M. A call for systematic reviews. Journal of General Internal Medicine 2004;19(12):1240‐1. - PMC - PubMed

Mummadi 2008

1. 1. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta‐analysis. Clinical Gastroenterology and Hepatology 2008;6(12):1396‐402. - PubMed

Musso 2003

1. 1. Musso G, Gambino R, Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37(4):909‐16. - PubMed

Neuschwander 2003

1. 1. Neuschwander‐Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37(5):1202‐19. - PubMed

RevMan 2008 [Computer program]

1. 1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.

Royle 2003

1. 1. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603. - PubMed

Schulz 1995

1. 1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed

Sweeting 2004

1. 1. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine. Statistics in Medicine 2004;23(9):1351‐75. - PubMed

Tellez‐Avila 2008

1. 1. Tellez‐Avila FI, Sanchez‐Avila F, García‐Saenz‐de‐Sicilia M, Chavez‐Tapia NC, Franco‐Guzman AM, Lopez‐Arce G, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World Journal of Gastroenterology 2008;14(30):4771‐5. - PMC - PubMed

Wang 2003

1. 1. Wang RT, Koretz RL, Yee HF Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. American Journal of Medicine 2003;115(7):554‐9. - PubMed

Wanless 1990

1. 1. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12(5):1106‐10. - PubMed

Wood 2008

1. 1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601‐5. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Wiley

• Other Literature Sources

  • H1 Connect

• Medical

  • MedlinePlus Health Information